Company Active LTD

Company profile

Ig Innovations Limited

Ig Innovations Limited is a UK company with status active founded in 2010 based in South East England.

CRN
07188244
Founded
2010
Age
16

Overview

Legal name
IG INNOVATIONS LIMITED
Region
South East England
Registered address
21 BLACKLANDS WAY
ABINGDON
OXFORDSHIRE
ENGLAND
OX14 1DY
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

3 levels 1 ultimate controller
1
Company Active LTD
Ig Innovations Limited
CRN 07188244
2
Direct controller Active LTD
3
Intermediate controller Active LTD
4
Ultimate controller
08142220
CRN 08142220

Company events

Reference milestones and recent Companies House filing stream events.

6 events
26 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

12 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

10 Oct
2024

Accounts With Accounts Type Small

Accounts PDF pending

AA | Transaction MzQzODMwNzYyN2FkaXF6a2N4 | Paper/PDF filed

Published 11 Oct 2024 12:27

12 Mar
2010

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2011
Funded years
2011, 2012
Age at first award
1 years

Projects

2012 Collaborative R&D

Project SABRINA (Sepsis Alert Biomarkers Resolved In a Novel Assay)

1 Jul 2012 to 30 Jun 2015

Awarded
£24,760
Total cost £49,520

A simple, easy to use, rapid, inexpensive, effective, point of care (POC) immunodiagnostic system for early confirmation of sepsis in at-risk patients is to be developed and validated. The biomarkers will include IL-6, C-reactive protein and soluble ICAM-1. These known biomarkers will be integrated via a new algorithm with other physical/clinical indicato...

2011 Collaborative R&D Lead participant

Investigation and validation of CD44vRA as a specific biomarker for rheumatoid arthritis targeted therapy for drug development - efficacy and companion

1 Sep 2011 to 31 Dec 2013

Awarded
£65,782
Total cost £138,226

Benefiting from over 15 years extensive research, this collaboration between MaimoniDex, Mologic Ltd, Ig Innovations and Swansea University Medical School is working to develop a new biomarker for early diagnosis and confirmation of rheumatoid arthritis. MaimoniDex has identified a CDD44 isoform termed CD44vRA as a potential therapeutic target. The collab...

Product types

Collaborative R&D